

Read Today's Paper

Tributes

11:02am Wednesday, September 2nd, 2026

Bundall Today  14 ° / 25 ° >**Gold Coast Bulletin**
We're for youHi, George  ▼My
News
Today's
PaperGold
Coast

World

Sport

Business

Opinion

Education


Lifestyle

Entertainment

Puzzles

**Business** [Stockhead](#)

Biocurious: It's spring, when a young




"Ooh that's nice but I would rather a statistically significant, randomised, double blinded trial readout." Pic: Getty Images

Modulated estradiol trial results are pending from Recce, Paradigm and Actinogen Medical

- The results are likely to make or break the companies' fortunes
- Alzheimer's drug developer Actinogen mulls a potential 'plan B' depression trial

Spring has sprung and what's not to love? Swooping magpies, hayfever and torrential rain notwithstanding, of course.



Stockhead
As recent failed late-stage results have shown, failure amounts to a shattering
ASX rises in spite of July's health care best performer

The S&P/ASX 200 rose 1.54% in August as healthcare popped 19% to be top the performing
The sector needs a win or two ... but no pressure at all.



Stockhead

Pilbara emerges as next copper frontier

The Pilbara has emerged as a copper growth story in Australian mining, with two mines heading towards construction. And there's more to come.

My News Feed

[Read More >](#)

Friends can call this one Zilosul



Two weeks ago, a data safety monitoring board completed its planned safety
review of around 80% of participants who had completed dosing.
Blood spilt as chair, Mayfair Hotel to be transformed after
directors ousted at Rone Aussie company \$7.5m sale
The review recommended the trial continue without modification, as did
similar reviews at the 20% and 50% mark.
Digital air traffic control towers not fit for WTH, says
Airservices boss

The company confirmed a September timeline for the interim readout.

But the timing remained “subject to completion of the required data cleaning, biometrics and independent review processes.”

Biocurious asked Paradigm investor relations director, former AFL player and Zilosul recipient Simon White for a further steer on timing, but he only had



You read that one here first!

Business Breaking News

Royals

National Breaking News

‘Uncertainty’: Why buyers are deserting market
Former prince Andrew accused of ‘sex crimes’ in the US
Ex-AFL star sues for \$1.2m over on-air nudity

The recruitment exceeded the targeted 466 patients. The study is being carried out across 57 sites, 41 of them in the US and 12 in Australia.

The primary endpoint is the change in pain intensity at day 112, as per weekly average measurement

RECOMMENDED TO FOLLOW

Gold Coast

Police Courts Gold Coast

Council

League

Opinion

Future Gold Coast

The idea of Zilosul is to reduce the inflammation involved in knee OA. Zilosul is also thought to prompt actual cartilage regeneration, which is a secondary endpoint.

How scammers now impersonate your bank

Investors are clearly punting on a positive result: the shares almost 30% in the last week and 40% over the last month.



Recce versus superbug

Trending now

Read More

Synthetic antibiotic developer Recce tentatively hopes for interim results from its pivotal Indonesian phase III trial by the end of October.

Secret plan to turn South

Straddie into 18-hole

Wendy this date is 12 mo



Shock as vandals target

Dolly Parton’s

Hollywood star, steal

flowers



The study road tests the company’s Recce 327 gel (R327G), for diabetic foot infections (DFIs).

‘Embarrassing’: How a

shattered friendship

Throughdown patent, give

Eyewear



Royals

Meghan faces hiring crisis over ‘rude’


interview claims



Around 20 million adult Indonesians have the condition – often ulcers – and one in three will develop diabetic leg ulcers.

Tragic detail after bank

Almost half of the hospital death in Times Square



Commercial Real Estate

Will require amputations. shock \$6m fight



The interim analysis applies to the first 155 patients, recruited across sites.

Police & Courts

Should the results stack up, Recce hopes the drug will be approved and Repeat offender has been court-released in Indonesia after assault



Former prince Andrew accused of 'sex crimes in the US'




Aussie trial, you beaut

Gold Coast

Council unveils homeless action plan after 7000 Middle-Eastern pharma co complaints licensing deal.



inding term sheet with a "leading a ten-year, exclusive multi-c Bank's sad call: \$211k wiped from Aussies



Meanwhile, Recce is carrying out an Australian-based phase III DFI trial. The study aims for Australian and US approval. **Stockhead**

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Last month an ethics committee approved a trial protocol amendment, which enables the addition of a randomised, active-controlled, non-inferiority study arm.

The 208 patients receive either R327G, or one of four physician-selected antibiotics for comparison.

"Patient dosing continues under the existing trial protocol, with recruitment and treatment ongoing ahead of implementation of this newly approved amendment," Recce says.

CEO James Graham says the ethics approval means recruitment can be widened to moderate, below-the-knee cases with multiple ulcers.

This accounts for around about 80% of the market.

Previously, the trial could only enrol below-the-ankle, mild cases with single ulcers. This cohort accounts for around 30% of the market.

"The is based on FDA accepted guidance and dramatically increases recruitment, market opportunity etcetera," Graham says.

The company plans an interim analysis at the 104-patient mark. This is likely to occur in late 2027 or early 2028.

"R327G has the potential to become the first standard of care used by physicians for the treatment of DFIs," Graham says.

R327 is one of four synthetic antibiotics Recce is developing.

The aim, of course, is to address the global problem of antibiotic-resistant superbugs.

Actinogen eyes Alzheimer's breakthrough

In its pursuit of a better treatment for Alzheimer's disease, Actinogen is comforted by late January's 'futility' interim analysis which showed that continuing the pivotal trial would be – well – far from pointless.

Dubbed Xanamia, the pivotal phase IIb/III trial road tests Xanamem (emestedastat).

Xanamem targets the suspected role of excess brain cortisol levels in triggering the disease. The notion of cortisol's involvement in the disease has been around for decades, but no one has quite been able to prove it.

Xanamem targets 11beta-hydroxy-steroid dehydrogenase type 1 (11beta-HSD1).

That's not a Holden Special Vehicle, but a cortisol-producing enzyme expressed in parts of the brain governing memory and mood.

In its full year results last Thursday, Actinogen confirmed the study remained on track for topline final results in November.

The company reports that 89% of participants (108) have moved on to an open-label extension study.

"The good news is that as people are on the drug for longer and we are not seeing any surprising safety concerns," says Actinogen CEO Dr Steven Gourlay.

Should the study pass master, Actinogen has agreed with the FDA and the European regulator on a streamlined further placebo-controlled pivotal trial of Xanamem.

"I'm feeling quite good about our program," Gourlay says.

"Our endpoints are clear and it is good high-quality drug development."

He stresses the trial relies on clinical outcomes – read: patient improvement – rather than high falutin' biomarker measures (our words).

Plan B from biotech space

In July the peer-reviewed British Journal of Psychiatry published a write-up of Actinogen's separate phase II proof-of-concept study.

The trial measured the effect of Xanamem on patients with major depression and cognitive impairment.

In short, the journal opined the drug was "worthy of further investigation."

Gourlay says an Alzheimer's therapy is "far and away" more valuable than a depression treatment.

But the company is open to pursuing a trial of depression in Alzheimer's patients.

“We are not saying we will or won’t do it,” he says.

“Maybe we can do a trial in older patients, perhaps with dementia or maybe not.

“If we could get that antidepressant activity as a feature for the drug into the prescribing information locally, that would be a really nice boost to the value of the molecule.”

He says the current interest in psychedelics highlights the need for new depression treatments beyond the current selective serotonin reuptake inhibitors (SSRIs, such as Prozac).

Gourlay dubs the chances of a complete Alzheimer’s flop as unlikely, “as we have so much data showing the activity of the drug in the brain”.

The company posted a full-year net loss of \$15.3m, having incurred \$19m of R&D costs. With \$16m in the bank, the company is well funded into 2027.

“If we found ourselves in a sticky situation, we have the time and the money and the right people to sort that out.”

Actinogen shares have blipped 48% year on year, but more recently shareholders have kept a lid on their excitement.

“Every CEO says we are hopelessly undervalued, but the net present value of a positive result is enormously higher than our current valuation,” Gourlay says.

A.k.a: 'we're dirt cheap, fill ya wellies'.

And – no - we are not licensed financial advisers.

Originally published as [Biocurious: It’s spring, when a young man’s fancy lightly turns to ... clinical trial results](#)

Advertisement

Membership	About Us	Contact Us	Our News Network	Our Partners	Our Apps
Subscription packages	About us	Help & support	Herald Sun	Buy Search Sell Classifieds	 
Group/Corporate Subscriptions	Meet the team	Story Tips	The Daily Telegraph	Foxsports	
Gold Coast Bulletin app	Job Opportunities	FAQs	The Courier Mail	Foxtel	
Today's Paper	Code of conduct	Standards of practice	The Advertiser	Hipages	
Newsletters	Subscription FAQs	Letter to the Editor	news.com.au	Kayo	
	Subscription Terms	Licensing & Reprints	The Australian	My Tributes	
	Financial Hardship Policy	Advertise with us	The Mercury	Punters	
			odds.com.au		
			Geelong Advertiser	racenet.com.au	
			The Cairns Post	News24 Australia	
			Townsville Bulletin	Coupons	
			The Chronicle		
			NT News		
			The Weekly Times		
			CODE Sports		

A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network.Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2026. All times AEST (GMT +10). Powered by WordPress.com VIP

[Privacy policy](#) [Relevant ads opt-out](#) [Cookie policy](#) [Terms of use](#)